Disclaimer

- Median Technologies, its directors, officers, advisors and employees make no representation or warranty as to statistical data or predictions contained in this presentation that were taken or derived from third party sources or industry publications; such statistical data and forecasts are used in this presentation for information purposes only.

- This presentation includes only summary information and should not be considered exhaustive. Objectives, statements and forecasts of Median Technologies contained in this document are provided only for illustrative purposes and are based on current views and assumptions of the management. These objectives, statements and forecast information, including expressed or implied statements regarding future revenues and sales, involve known and unknown risks as well as uncertainties that may affect actual results, performance or achievements of the Group which are likely to make them differ materially from those anticipated in the summary information. A certain number of factors may have consequences on actual results and developments and cause them to differ materially from those stated, whether expressed or implied, based on the forward-looking statements. Median Technologies disclaims any obligation or undertaking to disseminate an update or revision of the objectives, statements and information contained in this presentation in view of likely changes in the strategy or intentions of MEDIAN Technologies or in the course of events or conditions, assumptions or circumstances used in the preparation of such information, unless requested otherwise by law.

- Median Technologies Securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act").

- These documents are disclosed in a personal capacity only and for your own information on a confidential basis to you per your confidential obligation and may not be reproduced, redistributed or published (either internally or externally to your company), directly or indirectly, in whole or in part, in any capacity whatsoever, to any other person. U.S. investors must be "Accredited Investors" as defined in Regulation D of the Rules and Regulations promulgated under the Securities Act of 1933.

- This presentation is intended only for persons who (i) have professional experience in matters relating to investments within the meaning of "investment professionals" as defined in Article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion), Order 2005 (as amended) (the "Order"), (ii) who fall within the scope of Article 49 (2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, (iii) are not in the United Kingdom, or (iv) to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issuance or sale of securities may be lawfully communicated to or caused to be communicated to (all such persons together being referred to as "Qualified Persons"). This presentation is intended for Qualified Persons only and cannot be given to persons who are not Qualified Persons. Any investment or investment activity to which this presentation refers is permitted for Qualified Persons only and will be denied to any other person.

ALMDT
LISTED
ALTERNEXT

Listed: Alternext Euronext Growth Paris
IPO: May 2011, ISIN: FR0011049824 Ticker ALMST
Our Mission: Transforming imaging data into clinical information

Applying medicine, cloud computing, artificial intelligence to imaging technology to revolutionize the way drugs are developed and medical care is delivered

Leading technology company applying Artificial Intelligence for non-invasive imaging biomarker discovery

1 Credence Research 2 Globalization of P4 medicine, Radiology 2011 Feb; 258(2):571-82.
Mapping the Phenotype

Select patients for clinical trials

Monitor patients under treatment

Patient selection for targeted therapies

Screening and early detection of cancers and other chronic diseases

Predict treatment response

Predict patient prognosis or outcome
## Applying *imaging phenomics* to the patient journey

<table>
<thead>
<tr>
<th>THE MARKET</th>
<th>Clinical Trials</th>
<th>Patient Care</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Optimize the assessment of new drugs in clinical trials</strong></td>
<td><strong>Improve the screening, diagnosis, monitoring of patients and determine treatment effectiveness</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SOLUTIONS</th>
<th>iSee®</th>
<th>MediScan®</th>
<th>iBiopsy®</th>
<th>iBiopsy®</th>
</tr>
</thead>
<tbody>
<tr>
<td>median</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
iSee®

Configurable technology system with computer-assisted lesion detection and identification – to accelerate start-up, reduce errors and ensure data accuracy for clinical trials; addressing a ~$1b oncology clinical trials market
Automated clinical technology for lung cancer screening to transform identification and management of lesions – easy to use in reducing false positives and improving patient care addressing a ~$500m lung cancer market
Accelerate growth with dedicated focus

2017 Financial Highlights¹

- 21% Revenue growth to €7.69m
- €14.7m Net new business
- 23% Backlog increase to €23m indicating future revenue growth
- €28.3m Cash and cash equivalents

¹As of Dec 31, 2017, Unaudited. Full Audited 2017 Financials to be released on April 12.
Driving new business for continued growth

15 Basis point increase on our new business win conversion rate

16 New preferred-provider relationships, including the world’s largest biotech with differentiated products in oncology

>85 Studies with ~25% studies coming from top 20 pharmaceutical companies

>80 Hospitals where our system is deployed
...fueled by innovation and collaboration

Best-in-class partnerships with top pharma, CROs and hospitals

Syneos Health  CMIC  CMIC
Memorial Sloan Kettering Cancer Center  Centre Hospitalier Universitaire de Nice
Canon  medidata  medidata
Microsoft Research  ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS
Several top 10 Pharmaceutical
Operational excellence, innovation and new business to guide continued growth

For iCRO (iSee®) business, Median Technologies expects to deliver a 20-25% CAGR for the next three years

For iCRO (iSee®) business, Median Technologies expects to deliver a 40% gross margin by 2020

*Not audited
Continued focus to drive growth

2018 strategic imperatives:

- Develop additional strategic partnerships
- Increase backlog for iCRO (iSee®)
- Scale MediScan®
- Execute on clinical validation and partnering strategy for iBiopsy®
- Continue the growth story
Trends transforming the industry
Making medicine predictive, personalized, pre-emptive and participatory

- Deep Learning
- Genomics Phenomics
- Cloud Computing
- Artificial Intelligence
- Personalized Medicine
- Big Data

Patient-level –omics data and AI will enable personalized treatment

AI healthcare market: $6.6 billion by 2021¹

Multi-omics data integrated for complete view of the patient

~2,314 exabytes of HC data will be produced in 2020¹

Fueled by more powerful GPUs and sophisticated neural network algorithms

¹ Source: [median]
AI applied to cancer diagnosis

Patient 12: 5% probability this cancer is significant

Patient 174: 92% probability this cancer is significant
Continuing to innovate
2018 Roadmap

Q2: NASH study results (May)
Q2: Prostate study results (June)
Q2 - Q3: Lung study results (April, June, September)
Q4: Lung FDA 510(k) submission

With key partners

Prostate cancer

Lung cancer

Cloud computing; encryption

NASH disease

+ Top 10 Pharmaceutical
Median Technologies
An attractive investment

Leader in Imaging Phenomics

Serving an attractive and growing market

First-mover advantage with AI technology in medical imaging

Diverse revenue base

Deep and diverse customer relationships comprised of top pharma, mid-size and emerging companies in oncology and leading hospitals

Consistent focus on process and productivity leverage

Long-term consistent financial performance
Median Technologies
Management Team

Fredrik Brag
CEO, Chairman and Co-founder

Jeanne Hecht
Chief Operating Officer

Nick Campbell
Chief Commercial Officer

Bernard Reymann
Chief Financial Officer

James Golando
Chief of Operations

Loan Hoang-Sayag
Chief Medical Officer

Peter Bannister
Chief Technology Officer

Margie Kooman
VP, Head of Investor and Media Relations